NCT07865377

Serum Endogenous Estrogens, Estrogen Receptors, and Sirtuin-1 and -3 After Resveratrol Supplementation

← 임상시험 허브

레지스트리 요약

진행 상태
모집중 (RECRUITING)
질환/조건
Coronary Artery Disease (CAD), Menopause, Hormones
시험 유형
중재 연구 (INTERVENTIONAL)
단계
해당 없음(NA)
목적
예방
중재 유형
식이보충제, 기타
개입·치료
Trans-resveratrol, 1000 mg daily for 90 days, Placebo
Lead Sponsor
InCor Heart Institute (기타)

캐시 시각: 2026-10-09 02:19:05

ClinicalTrials.gov에서 보기

요약

Atherosclerotic coronary artery disease (CAD) is a leading cause of mortality among postmenopausal women. Resveratrol, a phenolic compound with antioxidant properties, may influence lipid metabolism, endothelial function, and platelet aggregation, while sirtuin-1 and sirtuin-3 regulate metabolic and hormonal responses to nutritional stimuli. This randomized, double-blind, placebo-controlled trial evaluates the effects of trans-resveratrol supplementation (1000 mg/day) versus placebo, over 90 days, on serum estradiol and estrone levels, gene expression of estrogen receptors alpha and beta, and sirtuins 1 and 3 in 80 postmenopausal women with CAD. Findings may inform therapeutic strategies for postmenopausal women with chronic coronary disease.

문의

이 시험 기반 리포트·메디컬라이팅이 필요하시면 문의해 주세요.